newsfilter
← Latest News
GlobeNewswire·

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad's Precise MRD, Prolaris, and MyRisk tests

SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting